ProMIS Neurosciences Inc PMN

The Bleeding continues

[retiredcop]

https://www.science.org/content/article/second-death-linked-potential-antibody-treatment-alzheimer-s-disease

Just a day before they are suppposed to present their data at the clinical trials conference , another potential death that could be attributed to brain bleeding, this time the severe reaction with a anti-clotting medicine.  
I am sure this is going to be on everyones mind and it will be very very interesting to see the questions and comments /opinions of experts after this presentation. Big question " will it impact how the FDA  looks at the fast track approval for this porduct "  
If you examine this report , that same thing jumps out at you " this company is trying to remove the amyloid plaque from the brain" 
This could have a very positive outlook for  companies like PMN that are dealing with the misfolded oligomer and ignoring the plaque as the main culprit in AD.

[bball67]

A second death from Lecanemab is significant but it might take one or two more deaths before things start to fall apart. Lower dosages to reduce this risk lowers any potential benefits. More deaths will possibly affect approval prospects. Even if approved,  doctors and neurologists will be loathe to recommend that a patient use the product from a liability standpoint. PMN 310 is different in

[M101]

Big thumbs up for this post RC. This why the aducanumab bandwagon strategy was always destined to fail, why we always should have had a strategy of strong differentiation along with modest respect, and therefore why Gene and Elliot had to be removed.  And why we as minor shareholders have to remain wary of management with divided loyalties.